Equities researchers at StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Free Report) in a research report issued on Tuesday. The firm set a “sell” rating on the stock.
Navidea Biopharmaceuticals Stock Performance
Shares of NYSE NAVB opened at $0.00 on Tuesday. The stock has a market capitalization of $100,080.00, a PE ratio of -0.02 and a beta of 1.47. The stock’s fifty day simple moving average is $0.03 and its two-hundred day simple moving average is $0.04. Navidea Biopharmaceuticals has a 12-month low of $0.00 and a 12-month high of $0.15.
About Navidea Biopharmaceuticals
Recommended Stories
- Five stocks we like better than Navidea Biopharmaceuticals
- What Are Dividends? Buy the Best Dividend Stocks
- AbbVie Stock: A Perfect Dip for Investors to Buy
- 3 Monster Growth Stocks to Buy Now
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- GitLab Stock Rebounds: The Inside Story of Its Comeback
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.